Trade Teva Pharmaceutical with LHFX

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company founded in 1901 in Jerusalem, headquartered in Tel Aviv, and dual-listed on the NYSE under TEVA (American Depositary Shares) and on the Tel Aviv Stock Exchange. Teva is the largest generic-pharmaceuticals manufacturer in the world by revenue, with operations in approximately 60 countries and a portfolio of more than 3,500 generic medicines. 2024 full-year revenue was approximately $16.5 billion, roughly flat year-over-year. Revenue mix split into Generic Medicines (53% of 2024 revenue), Innovative Medicines (28%, led by AUSTEDO and AJOVY), and Other (19%, including biosimilars, API sales, and over-the-counter products). Geographic mix is North America (54%), Europe (29%), International Markets (17%). The two key innovative growth drivers are AUSTEDO (deutetrabenazine, for tardive dyskinesia and Huntington's chorea) and AJOVY (fremanezumab, for migraine prevention). AUSTEDO XR revenue grew above 30% in 2024 and the franchise crossed $1.6 billion in annual revenue. The company is approximately three years into a multi-year turnaround under CEO Richard Francis, called the Pivot to Growth strategy. Key elements include divesting non-core API business, accelerating biosimilars (Humira biosimilar SIMLANDI launched in 2024), and prioritising the innovative pipeline including the olanzapine LAI (olanzapine long-acting injection) and TEV-749 risperidone LAI. Net debt was approximately $16.5 billion at year-end 2024, down meaningfully from the peak of $30+ billion in 2018. At LHFX you trade TEVA as a CFD on the NYSE ADS listing, not by buying the share. You profit or lose based on TEVA share-price movement, and you can go long or short. Settlement is in USD. Teva suspended its dividend in 2017 during the post-Actavis debt crisis and has not reinstated it as of late 2025. Dividend adjustments on the ex-dividend date are therefore not currently a factor. Maximum leverage on TEVA CFDs at LHFX is 1:20. Trading hours are US cash-equity hours, 14:30 to 21:00 UTC Monday to Friday. Commission is $3 per side on raw spreads. TEVA is one of the more legally and regulatory-volatile large-cap pharma names, with multi-year opioid-litigation and antitrust settlements continuing to affect cash flow. CFDs let you take a directional view with defined margin and the ability to short.

Open an LHFX account and fund it. Minimum deposit is $10. Card and crypto deposits settle in around 20 minutes. Open MetaTrader 5 or the LHFX Trade web platform and add TEVA to Market Watch. Trading hours are 14:30 to 21:00 UTC Monday to Friday. Spreads are raw with a commission of $3 per side per standard lot (100 shares), so a 1.00 lot round trip costs $6 plus the natural spread and smaller positions pay proportionally less. Size your position to your account, not to the 1:20 cap. TEVA is moderately volatile for a large-cap generic pharma name. Daily 1 to 3% moves are typical, earnings days produce 5 to 10% moves, and litigation-headline days can produce 6 to 12% moves with little warning. A reasonable starting position is one where a 10% adverse TEVA move costs no more than 2 to 3% of your account. Set a stop loss before entry. TEVA gaps on earnings and on US state-AG or federal litigation announcements that can land any trading day. Use limit orders around earnings (typically late January, May, July, and October) and ahead of major FDA decisions on innovative-pipeline assets. Note Israel-related geopolitical exposure. TEVA is dual-listed in Tel Aviv and US trading sometimes follows Tel Aviv direction in the Asian session. Worked example. On a $1,000 account at an $18 TEVA price, opening 14 shares of TEVA CFD requires $13 margin at 1:20 leverage (14 shares x $18 / 20). A 10% adverse move on those 14 shares costs $25, or 2.5% of your account. If you instead opened 50 shares ($45 margin), the same 10% move costs $90, or 9% of the account. Run the math on every entry before clicking buy.